{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:21:01Z","timestamp":1787757661579,"version":"build-2784847793"},"reference-count":49,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Obesity"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The safety, tolerability, pharmacokinetics, and efficacy of TERN\u2010601, a once\u2010daily, oral small\u2010molecule glucagon\u2010like peptide\u20101 (GLP\u20101) receptor agonist, were studied in Phase 1 and 2 clinical studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The Phase 1 (28\u2010day) and Phase 2 (12\u2010week), randomized, double\u2010blind, placebo\u2010controlled, multiple\u2010ascending\u2010dose studies evaluated the safety, tolerability, pharmacokinetics, and efficacy (change in weight, appetite, and gastric emptying) of TERN\u2010601 for adults with obesity or overweight.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the Phase 1 study, TERN\u2010601 produced dose\u2010dependent weight loss over 28\u2009days, with statistically significant reductions versus placebo at all doses. Treatment was associated with GLP\u20101\u2013consistent pharmacodynamic effects, including reduced appetite and delayed gastric emptying. In the Phase 2 study, TERN\u2010601 doses \u2265\u2009500\u2009mg resulted in significantly greater mean percentage weight loss at Week 12 versus placebo. Gastrointestinal treatment\u2010emergent adverse events were consistent with the GLP\u20101 receptor agonist class and dose\u2010related. Three participants in the Phase 2 study experienced transaminase elevations consistent with potential drug\u2010induced liver injury.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>TERN\u2010601 demonstrated modest, dose\u2010dependent weight loss with a gastrointestinal tolerability profile consistent with GLP\u20101 receptor agonists. However, liver safety findings observed in the Phase 2 study led to clinical development discontinuation. These data contribute to the overall understanding of oral small\u2010molecule GLP\u20101 receptor agonists in obesity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov identifier:\u00a0NCT06854952<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/oby.70271","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T07:06:27Z","timestamp":1785395187000},"page":"1742-1758","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oral\n                    <scp>GLP<\/scp>\n                    \u2010\n                    <scp>1RA TERN<\/scp>\n                    \u2010601 for Adults With Obesity\/Overweight: Placebo\u2010Controlled, Multiple\u2010Ascending\u2010Dose, Phase 1 and 2 Studies"],"prefix":"10.1002","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0822-0860","authenticated-orcid":false,"given":"W. Timothy","family":"Garvey","sequence":"first","affiliation":[{"name":"Department of Nutrition Sciences University of Alabama at Birmingham  Birmingham Alabama USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Rosenstock","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center  Dallas Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9912-1408","authenticated-orcid":false,"given":"Harold E.","family":"Bays","sequence":"additional","affiliation":[{"name":"Monroe Biomedical Research Louisville Metabolic and Atherosclerosis Research Center  Louisville Kentucky USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Denham","sequence":"additional","affiliation":[{"name":"Flourish Research  San Antonio Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Kohli","sequence":"additional","affiliation":[{"name":"Arizona Liver Health  Chandler Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Haines","sequence":"additional","affiliation":[{"name":"Neuroendocrine Unit, Department of Medicine Massachusetts General Hospital\/Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Jones","sequence":"additional","affiliation":[{"name":"Terns Pharmaceuticals, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Kwan","sequence":"additional","affiliation":[{"name":"Terns Pharmaceuticals, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2159-4162","authenticated-orcid":false,"given":"Erin","family":"Castelloe","sequence":"additional","affiliation":[{"name":"Terns Pharmaceuticals, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonya","family":"Marmon","sequence":"additional","affiliation":[{"name":"Terns Pharmaceuticals, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"Kuriakose","sequence":"additional","affiliation":[{"name":"Terns Pharmaceuticals, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8461-4453","authenticated-orcid":false,"given":"Cara","family":"Nelson","sequence":"additional","affiliation":[{"name":"Terns Pharmaceuticals, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.117.014803"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004871"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2025.01.021"},{"key":"e_1_2_11_5_1","volume-title":"StatPearls","author":"Collins L.","year":"2024"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(25)02105\u20101"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41387\u2010025\u201000397\u20104"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2025.2594493"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab848"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262\u2010023\u201001223\u20109"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(23)01185\u20106"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(23)01127\u20103"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/DISEASES13050129"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1155\/jobe\/9919810"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17040397"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2024.23332"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20108587(17)30236\u2010X"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000003919"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2026.0035"},{"key":"e_1_2_11_20_1","unstructured":"Eli Lilly and Company \u201cFDA Approves Lilly's Foundayo (Orforglipron) the Only GLP\u20101 Pill for Weight Loss That can be Taken any Time of Day Without Food or Water Restrictions \u201d published April 1 2026 accessed April 9 2026 https:\/\/www.prnewswire.com\/news\u2010releases\/fda\u2010approves\u2010lillys\u2010foundayo\u2010orforglipron\u2010the\u2010only\u2010glp\u20101\u2010pill\u2010for\u2010weight\u2010loss\u2010that\u2010can\u2010be\u2010taken\u2010any\u2010time\u2010of\u2010day\u2010without\u2010food\u2010or\u2010water\u2010restrictions\u2010302731485.html."},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511774"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(25)02165\u20108"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15643"},{"key":"e_1_2_11_24_1","unstructured":"Pfizer \u201cPfizer Provides Update on GLP\u20101\u2010RA Clinical Development Program for Adults With Obesity and Type 2 Diabetes Mellitus \u201d published June 26 2023 accessed April 9 2026 https:\/\/www.pfizer.com\/news\/press\u2010release\/press\u2010release\u2010detail\/pfizer\u2010provides\u2010update\u2010glp\u20101\u2010ra\u2010clinical\u2010development."},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.14493"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16534"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2023.155710"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010021\u201001391\u2010w"},{"key":"e_1_2_11_29_1","unstructured":"Pfizer \u201cPfizer Provides Update on Oral GLP\u20101 Receptor Agonist Danuglipron \u201d published April 14 2025 accessed April 9 2026 https:\/\/www.pfizer.com\/news\/press\u2010release\/press\u2010release\u2010detail\/pfizer\u2010provides\u2010update\u2010oral\u2010glp\u20101\u2010receptor\u2010agonist."},{"key":"e_1_2_11_30_1","unstructured":"Terns \u201cTerns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results for TERN\u2010601 \u201d 2024 accessed April 9 2026 https:\/\/ir.ternspharma.com\/news\u2010releases\/news\u2010release\u2010details\/terns\u2010pharmaceuticals\u2010announces\u2010positive\u2010phase\u20101\u2010clinical\u2010trial\/."},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.2337\/db23\u2010767\u2010P"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.3390\/scipharm93020026"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.2337\/db25-307-OR"},{"key":"e_1_2_11_34_1","unstructured":"Terns \u201cTerns Pharmaceuticals Reports Topline 12\u2010Week Data From its Phase 2 Trial Evaluating Oral GLP\u20101 Receptor Agonist TERN\u2010601 in Obesity \u201d 2025 accessed April 9 2026 https:\/\/ir.ternspharma.com\/news\u2010releases\/news\u2010release\u2010details\/terns\u2010pharmaceuticals\u2010reports\u2010topline\u201012\u2010week\u2010data\u2010its\u2010phase\u20102."},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0801083"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365\u20102982.2001.00249.x"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002820"},{"key":"e_1_2_11_38_1","unstructured":"US Food and Drug Administration \u201cDrug\u2010Induced Liver Injury: Premarketing Clinical Evaluation \u201d published July 2009 accessed April 9 2026 https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/drug\u2010induced\u2010liver\u2010injury\u2010premarketing\u2010clinical\u2010evaluation."},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010024\u201001511\u20108"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20445"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302392"},{"key":"e_1_2_11_42_1","unstructured":"Regor Therapeutics \u201cRegor Releases Phase 2a Topline Results for RGT\u2010075 an Oral Once\u2010Daily Small Molecule GLP\u20101R Agonist and Begins Phase 2b Study in the US for the Treatment of Obesity \u201d published January 10 2025 accessed April 9 2026 https:\/\/www.prnewswire.com\/news\u2010releases\/regor\u2010releases\u2010phase\u20102a\u2010topline\u2010results\u2010for\u2010rgt\u2010075\u2010an\u2010oral\u2010once\u2010daily\u2010small\u2010molecule\u2010glp\u20101r\u2010agonist\u2010and\u2010begins\u2010phase\u20102b\u2010study\u2010in\u2010the\u2010us\u2010for\u2010the\u2010treatment\u2010of\u2010obesity\u2010302348153.html."},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/1753\u20100407.70063"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2025.8222"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.3224"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411892"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.q1645"},{"key":"e_1_2_11_49_1","doi-asserted-by":"crossref","unstructured":"R.Bozick S. D.Donofry andK. M.Rancano \u201cNew Weight Loss Drugs: GLP\u20101 Agonist Use and Side Effects in the United States \u201d RAND published August 6 2025 accessed April 9 2026 https:\/\/www.rand.org\/pubs\/research_reports\/RRA4153\u20101.html.","DOI":"10.7249\/rhq-13-01-03"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038"}],"container-title":["Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/oby.70271","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/oby.70271","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/oby.70271","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:48:41Z","timestamp":1787755721000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/oby.70271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":49,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1002\/oby.70271"],"URL":"https:\/\/doi.org\/10.1002\/oby.70271","archive":["Portico"],"relation":{},"ISSN":["1930-7381","1930-739X"],"issn-type":[{"value":"1930-7381","type":"print"},{"value":"1930-739X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"2026-04-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}